Product Description
ABT-639 is a peripherally acting highly selective T-type Ca(v)3.2 calcium channel blocker that has demonstrated analgesic efficacy in preclinical models and may have the potential to reduce spontaneous fiber activity. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26035253/)
Mechanisms of Action: Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Neuropathic Pain|Neuralgia|Peripheral Nervous System Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2011-005127-40 | P2 |
Completed |
Neuropathic Pain |
2012-11-13 |
|
| M13-383 | P2 |
Completed |
Neuropathic Pain|Peripheral Nervous System Diseases|Neuralgia |
2012-11-01 |
|
| 2010-024359-99 | P2 |
Completed |
Neuropathic Pain |
2011-10-26 |
|
| M11-891 | P2 |
Completed |
Neuralgia|Neuropathic Pain |
2011-10-01 |